Difference between revisions of "Rhabdomyosarcoma, pediatric"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
Line 10: Line 10:
 
==COG ARST0431==
 
==COG ARST0431==
  
===Protocol {{#subobject:9a3f8d|Variant=1}}===
 
  
====Vincristine and Irinotecan====
+
===Vincristine and Irinotecan===
 
  Weeks 1, 4, 20, 23, 47, & 50
 
  Weeks 1, 4, 20, 23, 47, & 50
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
Line 21: Line 20:
 
*[[Irinotecan (Camptosar)]] 50 mg/m<sup>2</sup> (maximum dose of 100 mg/day) IV over 60 minutes once per day on days 1 through 5
 
*[[Irinotecan (Camptosar)]] 50 mg/m<sup>2</sup> (maximum dose of 100 mg/day) IV over 60 minutes once per day on days 1 through 5
  
====Vincristine Monotherapy====
+
===Vincristine Monotherapy===
 
  Weeks 2, 3, 5, 8, 12, 16, 21, 22, 24, 29, 33, 42, 43, 48, & 50  
 
  Weeks 2, 3, 5, 8, 12, 16, 21, 22, 24, 29, 33, 42, 43, 48, & 50  
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
Line 27: Line 26:
 
**Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
 
**Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
 
**Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
 
**Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
====Off Chemotherapy Weeks====
+
===Off Chemotherapy Weeks===
 
  Weeks 6, 10, 14, 18, 19, 25, 27, 31, 34, 36, 37, 39, 40, 45, 46, 49, 52, 53, & 54
 
  Weeks 6, 10, 14, 18, 19, 25, 27, 31, 34, 36, 37, 39, 40, 45, 46, 49, 52, 53, & 54
====Vincristine, Doxorubicin, and Cyclophosphamide====
+
===Vincristine, Doxorubicin, and Cyclophosphamide===
 
  Weeks 7, 11, 15, 28, & 32
 
  Weeks 7, 11, 15, 28, & 32
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
Line 46: Line 45:
  
  
====Ifosfamide and Etoposide====
+
===Ifosfamide and Etoposide===
 
  Weeks 9, 13, 17, 26, & 30
 
  Weeks 9, 13, 17, 26, & 30
 
*[[Ifosfamide (Ifex)]] by the following age-based criteria:
 
*[[Ifosfamide (Ifex)]] by the following age-based criteria:
Line 58: Line 57:
 
**Age < 1 year: 50 mg/m<sup>2</sup> IV over 30 to 60 minutes once per day on days 1 through 5
 
**Age < 1 year: 50 mg/m<sup>2</sup> IV over 30 to 60 minutes once per day on days 1 through 5
  
====Vincristine, Dactinomycin, and Cyclophosphamide====
+
===Vincristine, Dactinomycin, and Cyclophosphamide===
 
  Weeks 35, 38, 41, & 44
 
  Weeks 35, 38, 41, & 44
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
 
*[[Vincristine (Oncovin)]] by the following age-based criteria:
Line 74: Line 73:
 
**Age < 3 years: 8 mg/kg at hour 0, 4, and 8 from the start of each [[Cyclophosphamide (Cytoxan)]] infusion on days 1
 
**Age < 3 years: 8 mg/kg at hour 0, 4, and 8 from the start of each [[Cyclophosphamide (Cytoxan)]] infusion on days 1
  
=====References=====
+
====References====
 
# '''COG ARST0431:''' Weigel BJ, Lyden E, Anderson JR, Meyer WH, Parham DM, Rodeberg DA, Michalski JM, Hawkins DS, Arndt CAS. Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients with High-Risk Rhabdomyosarcoma: A Report from the Children's Oncology Group. Journal of Clinical Oncology. 2016 Oct;34(2):117-122. [https://doi.org/10.1200/jco.2015.63.4048 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070550/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26503200/ PubMed] NCT00354744
 
# '''COG ARST0431:''' Weigel BJ, Lyden E, Anderson JR, Meyer WH, Parham DM, Rodeberg DA, Michalski JM, Hawkins DS, Arndt CAS. Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients with High-Risk Rhabdomyosarcoma: A Report from the Children's Oncology Group. Journal of Clinical Oncology. 2016 Oct;34(2):117-122. [https://doi.org/10.1200/jco.2015.63.4048 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070550/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26503200/ PubMed] NCT00354744
  

Revision as of 16:13, 19 May 2022

Section editor transclusions

0 regimens on this page
0 variants on this page


Upfront Therapy

COG ARST0431

Vincristine and Irinotecan

Weeks 1, 4, 20, 23, 47, & 50
  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
Administer Vincristine (Oncovin) before Irinotecan (Camptosar)
  • Irinotecan (Camptosar) 50 mg/m2 (maximum dose of 100 mg/day) IV over 60 minutes once per day on days 1 through 5

Vincristine Monotherapy

Weeks 2, 3, 5, 8, 12, 16, 21, 22, 24, 29, 33, 42, 43, 48, & 50 
  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1

Off Chemotherapy Weeks

Weeks 6, 10, 14, 18, 19, 25, 27, 31, 34, 36, 37, 39, 40, 45, 46, 49, 52, 53, & 54

Vincristine, Doxorubicin, and Cyclophosphamide

Weeks 7, 11, 15, 28, & 32
  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Doxorubicin (Adriamycin) by the following age-based criteria:
    • Age ≥ 1 year: 37.5 mg/m2 (Total dose per week of 75 mg/m2) IV over 24 hours once per day on days 1 through 2
    • Age < 1 year: 18.75 mg/m2 IV over 24 hours once per day on days 1 through 2
  • Cyclophosphamide (Cytoxan) by the following age-based criteria:
    • Age ≥ 3 years: 1200 mg/m2 IV over 1 hour once per day on day 1
    • Age < 3 years: 40mg/kg IV over 1 hour once per day on day 1
  • Mesna (Mesnex) by the following age-based criteria:


Ifosfamide and Etoposide

Weeks 9, 13, 17, 26, & 30
  • Ifosfamide (Ifex) by the following age-based criteria:
    • Age ≥ 1 year: 1800 mg/m2 IV over 1 hour once per day on days 1 through 5
    • Age < 1 year: 900 mg/m2 IV over 1 hour once per day on days 1 through 5
  • Mesna (Mesnex) by the following age-based criteria:
    • Age ≥ 3 years: 360 mg/m2 at hour 0, 4, and 8 from the start of each Ifosfamide (Ifex) infusion on days 1 through 5
    • Age < 3 years: 180 mg/m2 at hour 0, 4, and 8 from the start of each Ifosfamide (Ifex) infusion on days 1 through 5
  • Etoposide (Vepesid) by the following age-based criteria:
    • Age ≥ 1 year: 100 mg/m2 IV over 30 to 60 minutes once per day on days 1 through 5
    • Age < 1 year: 50 mg/m2 IV over 30 to 60 minutes once per day on days 1 through 5

Vincristine, Dactinomycin, and Cyclophosphamide

Weeks 35, 38, 41, & 44
  • Vincristine (Oncovin) by the following age-based criteria:
    • Age ≥ 3 years: 1.5 mg/m2 (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age ≥ 1 year to < 3 years: 0.05 mg/kg (maximum dose of 2 mg) IV push over 1 minute once on day 1
    • Age < 1 year: 0.025 mg/kg IV push over 1 minute once on day 1
  • Dactinomycin (Cosmegen) by the following age-based criteria:
    • Age ≥ 1 year: 0.045 mg/kg (maximum dose of 2.5 mg) IV push over 1 to 5 minutes once per day on day 1
    • Age < 1 year: 0.025 mg/kg IV over 1 to 5 minutes once per day on day 1
  • Cyclophosphamide (Cytoxan) by the following age-based criteria:
    • Age ≥ 3 years: 1200 mg/m2 IV over 1 hour once per day on day 1
    • Age < 3 years: 40mg/kg IV over 1 hour once per day on day 1
  • Mesna (Mesnex) by the following age-based criteria:

References

  1. COG ARST0431: Weigel BJ, Lyden E, Anderson JR, Meyer WH, Parham DM, Rodeberg DA, Michalski JM, Hawkins DS, Arndt CAS. Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients with High-Risk Rhabdomyosarcoma: A Report from the Children's Oncology Group. Journal of Clinical Oncology. 2016 Oct;34(2):117-122. link to original article link to PMC article PubMed NCT00354744